NCT04162015 - A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Malignant Pleural Mesothelioma

Interventions

DRUG

Nivolumab

nivolumab 360 mg

DRUG

Pemetrexed

500 mg/m\^2

DRUG

Cisplatin or Carboplatin

cisplatin 75 mg/m2 or carboplatin AUC=5

Trial Locations (7)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Westchester, Harrison

Memorial Sloan Kettering Nassau, Uniondale

Memorial Sloan Kettering Commack, Commack

Memoiral Sloan Kettering Basking Ridge, Basking Ridge

Memorial Sloan Kettering Monmouth, Middletown

Memorial Sloan Kettering Bergen, Montvale